Lapatinib Pharos (Lapatinib)

Lapatinib reversibly binds to the intracellular kinase domains of EGFR (ErbB1) and HER2 (ErbB2). This blocks receptor autophosphorylation and downstream MAPK and PI3K/AKT pathways, leading to reduced cell proliferation and increased apoptosis in tumors that rely on HER2 signaling.

The appropriate dose of Lapatinib Pharos is determined by the prescribing physician based on the specific indication, patient characteristics, and any concomitant therapies. Dosing recommendations are provided in the product’s prescribing information and should be followed precisely.

Safety data for Lapatinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while receiving treatment. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lapatinib is a small‑molecule oral inhibitor that targets both HER2 and EGFR, whereas agents such as trastuzumab and pertuzumab are monoclonal antibodies administered intravenously and primarily target HER2 extracellularly. The oral route offers convenience, but therapeutic choice depends on disease setting, prior treatments and patient tolerance.

Lapatinib Pharos should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not store in the bathroom or near heat sources, and keep the product out of reach of children.

Lapatinib Pharos is taken orally, usually with a low‑fat meal or as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed, unless the product label specifies otherwise.

The most serious adverse events include cardiac dysfunction such as decreased left ventricular ejection fraction, severe skin reactions like Stevens‑Johnson syndrome, interstitial lung disease, and significant hepatotoxicity. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Lapatinib is contraindicated in patients with known hypersensitivity to lapatinib or any of its excipients, and it should be avoided in individuals with pre‑existing severe cardiac impairment, uncontrolled liver disease, or those taking prohibited strong CYP3A4 inducers without appropriate dose adjustment.